Maria-Clemencia Hernandez

This inventor holds 10 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maria-Clemencia Hernandez. Retrieved from https://idiyas.com/inventor/maria-clemencia-hernandez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 16)

% Patents Active = 90.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Delemont, CH (2012 - 2014)
Delémont, CH (2014 - 2023)
Basel, CH (2021 - 2023)

Company Filing History:

10 out of 5,026

Hoffmann-La Roche Inc.

patents

Years Active: 2012-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747235 - Triazolyl derivatives as GABAα5 PAM (2026-09-29),

2. 12692271 - Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators (2026-07-28),

3. 12365687 - Benzodiazepine derivatives as GABA A gamma 1 PAM (2025-07-22),

4. 12344614 - Benzodiazepine derivatives as GABA a GAMMA1 PAM (2025-07-01),

5. 11840528 - Isoxazolyl ether derivatives as GABAα5 PAM (2023-12-12),

6. 11739095 - Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators (2023-08-29),

7. 11091471 - Isoxazolyl ether derivatives as GABAα5 PAM (2021-08-17),

8. 8835425 - Use of selective GABA A α5 negative allosteric modulators for the treatment of central nervous system conditions (2014-09-16),

9. 8742097 - Triazole compounds I (2014-06-03),

10. 8173652 - Isoxazole-isoxazoles and isoxazole-isothiazoles (2012-05-08),

Title: Innovator Maria-Clemencia Hernandez: Pioneering Advances in Neurological Treatments

Introduction

Maria-Clemencia Hernandez, an accomplished inventor based in Delémont, Switzerland, has made significant contributions to the field of pharmaceuticals. With a total of eight patents to her name, her work focuses on developing novel compounds that have the potential to address various neurological disorders.

Latest Patents

Among her most recent patents are innovative benzodiazepine derivatives designed as GABA A gamma 1 positive allosteric modulators. These groundbreaking inventions include heterocyclic compounds that come with a general formula for their composition. The patents also encompass pharmaceutical compositions involving these compounds, along with processes for manufacturing them. The therapeutic applications of these compounds aim to treat or prevent acute and chronic neurological disorders, as well as cognitive disorders.

Career Highlights

Maria-Clemencia has dedicated her career to advancing medical science and improving patient outcomes through her innovative work. As a part of Hoffmann-La Roche Inc., she has been instrumental in driving research and development efforts that lead to significant advancements in neurological therapies.

Collaborations

Throughout her career, Maria-Clemencia has collaborated with esteemed colleagues such as Giuseppe Cecere and Andrew William Thomas. These partnerships have fostered an environment of innovation and have been vital in bringing her creative ideas to fruition.

Conclusion

Maria-Clemencia Hernandez is a notable figure in the realm of pharmaceutical innovation. Her dedication to her craft and her impactful inventions are setting new benchmarks in the treatment of neurological disorders. As she continues to pursue her passion for research, her contributions are likely to yield further advancements that can improve countless lives.

Profile summary based on public USPTO records.